Strategic partnerships Opportunity to partner with veterinary and human healthcare networks through expanded access programs, leveraging HbO2 Therapeutics’ FDA EMA approved veterinary product Oxyglobin and investigational Hemopure to broaden patient access channels.

Specialized market niche Position HbO2 as a niche oxygen-carrying solution provider for life-threatening anemia cases where blood transfusion is limited or contraindicated, targeting hospitals, trauma centers, and organ systems with transfusion constraints.

Regulatory leverage Leverage multi-region approvals and investigational status to open pilot programs, compassionate use collaborations, and early access deals, highlighting geographic regions with existing approvals (South Africa, Russia) to inform targeted outreach.

Clinical and vet reach Cross-sell opportunities between human and veterinary channels by promoting Oxyglobin’s established veterinary approval to veterinary clinics and animal hospitals while aligning messaging for human use in emergency medicine, surgical anemia, and transfusion-relief scenarios.

Financial and growth signals Utilize IPO indication and modest revenue/funding levels to craft investment-grade outreach focused on strategic investors and grant-backed partnerships, emphasizing scalable manufacturing capabilities and potential for expanded access programs.